\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ abnormalities\\ noted\\ during\\ testicular\\ exam\\.\ \(0\)\
\-\ annual\\ followup\\ ultrasound\\.\ \(0\)\
\-\ ultrasound\\ of\\ the\\ bilateral\\ testes\\ demonstrates\\ multiple\\ 1\\-2\\ mm\\ hyperechoic\\ nonshadowing\\ foci\\ present\\ throughout\\ the\\ testicular\\ parenchyma\\.\ \(0\)\
\-\ testicular\\ microlithiasis\ \(11\)\
\-\ punctate\\ hyperechoic\\ foci\\:\\ \\(microlithiasis\\ ddx\\)\ \(0\)\
\-\ 1\\.\\ granulomatous\\ changes\\ \ \(1\)\
\-\ 2\\.\\ scar\\ \ \(1\)\
\-\ 3\\.\\ benign\\ adenomatoid\\ tumor\\ \ \(1\)\
\-\ 4\\.\\ hemorrhage\\ with\\ infarction\ \(1\)\
\-\ 5\\.\\ post\\-inflammatory\\ changes\ \(2\)\
\-\ 6\\.\\ large\\ calcifying\\ sertoli\\ cell\\ tumor\ \(0\)\
\-\ 36\\ year\\ old\\ male\\ with\\ chronic\\ testicular\\ pain\\ for\\ several\\ years\\.\\ requests\\ evaluation\\ for\\ pathology\\.\ \(0\)\
\-\ classic\\ testicular\\ microlithiasis\\ is\\ defined\\ as\\ greater\\ than\\ 5\\ hyperechoic\\ nonshadowing\\ foci\\ \\(in\\ one\\ image\\)\\ throughout\\ the\\ parenchyma\\ of\\ the\\ testes\\.\\ although\\ frequently\\ symmetric\\,\\ it\\ can\\ often\\ times\\ be\\ asymptomatic\\ and\\ seen\\ on\\ the\\ periphery\\ of\\ the\\ testis\\.\\ in\\ patients\\ where\\ less\\ than\\ 5\\ foci\\ are\\ present\\ per\\ image\\,\\ limited\\ microlithiasis\\ is\\ diagnosed\\.\\ \ \(0\)\
\-\ previously\\ it\\ was\\ thought\\ that\\ germ\\ cell\\ tumors\\ were\\ present\\ in\\ up\\ to\\ 40\\%\\ of\\ patients\\ with\\ microlithiasis\\ \\(ref\\ 1\\ and\\ 2\\)\\.\\ this\\ corresponded\\ to\\ approximately\\ 21\\ times\\ increased\\ risk\\ of\\ testicular\\ cancer\\.\\ due\\ to\\ these\\ limited\\ studies\\,\\ there\\ were\\ controversial\\ recommendations\\ to\\ perform\\ yearly\\ ultrasound\\ follow\\-up\\ examinations\\ in\\ these\\ patients\\.\\ these\\ studies\\ were\\ performed\\ with\\ small\\ patient\\ numbers\\ in\\ individuals\\ referred\\ for\\ ultrasound\\ due\\ to\\ identification\\ of\\ testicular\\ masses\\.\\ \ \(0\)\
\-\ more\\ recent\\ studies\\ \\(ref\\ 3\\ and\\ 4\\)\\ were\\ performed\\ with\\ much\\ larger\\ study\\ subjects\\ involving\\ all\\ patients\\ undergoing\\ testicular\\ ultrasound\\ for\\ any\\ reason\\.\\ they\\ have\\ demonstrated\\ less\\ risk\\ \\(8\\%\\)\\ of\\ testicular\\ neoplasms\\ in\\ patients\\ with\\ microlithiasis\\ than\\ previously\\ thought\\.\\ moreover\\,\\ with\\ an\\ average\\ follow\\-up\\ ultrasound\\ average\\ of\\ 42\\ months\\,\\ no\\ additional\\ tumors\\ were\\ identified\\ in\\ these\\ patients\\ \\(ref\\ 4\\)\\.\\ the\\ authors\\ of\\ these\\ studies\\ suggested\\ that\\ it\\ would\\ not\\ significantly\\ affect\\ mortality\\/morbidity\\ to\\ continue\\ annual\\ ultrasound\\ surveillance\\.\\ they\\ suggested\\ a\\ more\\ reasonable\\ approach\\ to\\ patients\\ with\\ limited\\/classic\\ microlithiasis\\ would\\ be\\ to\\ perform\\ annual\\ physical\\ exams\\ and\\ montly\\ self\\-exams\\.\\ \ \(0\)\
\-\ references\\:\\ \ \(0\)\
\-\ 1\\.\\ backus\\,\\ et\\.al\\.\\,\\ radiology\\ 1994\\;\\ 192\\:781\\-785\\.\\ \\(42\\ patients\\)\\ \ \(0\)\
\-\ 2\\.\\ miller\\,\\ et\\.al\\.\\,\\ j\\ clin\\ ultrasound\\ 1996\\;\\ 24\\:197\\-202\\.\\ \ \(0\)\
\-\ 3\\.\\ bennett\\,\\ et\\ al\\.\\,\\ testicular\\ microlithiasis\\:\\ us\\ follow\\-up\\.\\ radiology\\.\\ 2001\\;218\\:359\\-363\\.\\ \ \(0\)\
\-\ 4\\.\\ middleton\\,\\ et\\ al\\.\\,testicular\\ microlithiasis\\:\\ prospective\\ analysis\\ of\\ prevalence\\ and\\ associated\\ tumor\\.\\ radiology\\ 2002\\;224\\:425\\-428\\.\\ \\(1079\\ patients\\,\\ 195\\ with\\ testicular\\ microlithiasis\\)\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ microlithiasis\\:\\ 0\\.4867598730827815\ \(0\)\
\-\ testicular\\:\\ 0\\.4436778063666282\ \(0\)\
\-\ patients\\:\\ 0\\.19960285234910968\ \(0\)\
\-\ ultrasound\\:\\ 0\\.19453910118260506\ \(0\)\
\-\ ref\\:\\ 0\\.14477099872817248\ \(0\)\
\-\ foci\\:\\ 0\\.12889007575056163\ \(0\)\
\-\ et\\:\\ 0\\.12353208771521874\ \(0\)\
\-\ studies\\:\\ 0\\.1156781041476379\ \(0\)\
\-\ these\\:\\ 0\\.11131332468171669\ \(0\)\
\-\ annual\\:\\ 0\\.10931495188242052\ \(0\)\
\-\ hyperechoic\\:\\ 0\\.10887844011982237\ \(0\)\
\-\ nonshadowing\\:\\ 0\\.10877862505250417\ \(0\)\
\-\ were\\:\\ 0\\.10160938291783797\ \(0\)\
\-\ radiology\\:\\ 0\\.09472415046705229\ \(0\)\
\-\ limited\\:\\ 0\\.09439933636360195\ \(0\)\
\-\ testes\\:\\ 0\\.08734570641490692\ \(0\)\
\-\ average\\:\\ 0\\.08216655794500806\ \(0\)\
\-\ perform\\:\\ 0\\.08132858248056675\ \(0\)\
\-\ exams\\:\\ 0\\.08003583145712467\ \(0\)\
\-\ to\\:\\ 0\\.07884716221551302\ \(0\)\
\-\ up\\:\\ 0\\.07800605306573406\ \(0\)\
\-\ of\\:\\ 0\\.07715080944667158\ \(0\)\
\-\ suggested\\:\\ 0\\.07378832949107567\ \(0\)\
\-\ times\\:\\ 0\\.07095758699883126\ \(0\)\
\-\ 42\\:\\ 0\\.07008953021255629\ \(0\)\
\-\ with\\:\\ 0\\.06947721633323875\ \(0\)\
\-\ in\\:\\ 0\\.06865169206558806\ \(0\)\
\-\ thought\\:\\ 0\\.06807952381015661\ \(0\)\
\-\ than\\:\\ 0\\.06704484859086107\ \(0\)\
\-\ parenchyma\\:\\ 0\\.06405121175028052\ \(0\)\
\-\ previously\\:\\ 0\\.06329570338982053\ \(0\)\
\-\ tumor\\:\\ 0\\.06186294683683702\ \(0\)\
\-\ present\\:\\ 0\\.060689036569675676\ \(0\)\
\-\ it\\:\\ 0\\.060541616141355795\ \(0\)\
\-\ backus\\:\\ 0\\.060245141369423695\ \(0\)\
\-\ 1079\\:\\ 0\\.060245141369423695\ \(0\)\
\-\ classic\\:\\ 0\\.05897436140386808\ \(0\)\
\-\ montly\\:\\ 0\\.05825691850673798\ \(0\)\
\-\ throughout\\:\\ 0\\.057988484468975116\ \(0\)\
\-\ tumors\\:\\ 0\\.057988484468975116\ \(0\)\
\-\ requests\\:\\ 0\\.05671473304275445\ \(0\)\
\-\ risk\\:\\ 0\\.0563382043915571\ \(0\)\
\-\ they\\:\\ 0\\.0563382043915571\ \(0\)\
\-\ would\\:\\ 0\\.05581489790976745\ \(0\)\
\-\ subjects\\:\\ 0\\.05545467577019378\ \(0\)\
\-\ the\\:\\ 0\\.05506546318044837\ \(0\)\
\-\ less\\:\\ 0\\.053641443839399616\ \(0\)\
\-\ calcifying\\:\\ 0\\.053466452907508066\ \(0\)\
\-\ corresponded\\:\\ 0\\.053466452907508066\ \(0\)\
\-\ middleton\\:\\ 0\\.053466452907508066\ \(0\)\
\-\ 195\\:\\ 0\\.053466452907508066\ \(0\)\
\-\ numbers\\:\\ 0\\.05192426744352453\ \(0\)\
\-\ bennett\\:\\ 0\\.05192426744352453\ \(0\)\
\-\ moreover\\:\\ 0\\.05126556154322758\ \(0\)\
\-\ image\\:\\ 0\\.05042605428187838\ \(0\)\
\-\ sertoli\\:\\ 0\\.05011102053341887\ \(0\)\
\-\ miller\\:\\ 0\\.04959884692702217\ \(0\)\
\-\ for\\:\\ 0\\.04779631502691482\ \(0\)\
\-\ changes\\:\\ 0\\.04765231130103439\ \(0\)\
\-\ performed\\:\\ 0\\.04664660517255938\ \(0\)\
\-\ yearly\\:\\ 0\\.046475095943997666\ \(0\)\
\-\ authors\\:\\ 0\\.04616788176872151\ \(0\)\
\-\ recommendations\\:\\ 0\\.045873744571733946\ \(0\)\
\-\ reasonable\\:\\ 0\\.04559161638031109\ \(0\)\
\-\ prospective\\:\\ 0\\.04559161638031109\ \(0\)\
\-\ due\\:\\ 0\\.04532318234254822\ \(0\)\
\-\ cell\\:\\ 0\\.0451045638655191\ \(0\)\
\-\ adenomatoid\\:\\ 0\\.04505972469787546\ \(0\)\
\-\ controversial\\:\\ 0\\.04505972469787546\ \(0\)\
\-\ 1994\\:\\ 0\\.04480838132779225\ \(0\)\
\-\ reason\\:\\ 0\\.043885521709048234\ \(0\)\
\-\ identification\\:\\ 0\\.04367285320745346\ \(0\)\
\-\ more\\:\\ 0\\.04329586552845954\ \(0\)\
\-\ examinations\\:\\ 0\\.04307150183518975\ \(0\)\
\-\ surveillance\\:\\ 0\\.04307150183518975\ \(0\)\
\-\ prevalence\\:\\ 0\\.04307150183518975\ \(0\)\
\-\ testis\\:\\ 0\\.042697833484794126\ \(0\)\
\-\ 1996\\:\\ 0\\.042697833484794126\ \(0\)\
\-\ clin\\:\\ 0\\.041377416169491595\ \(0\)\
\-\ individuals\\:\\ 0\\.04122878289337009\ \(0\)\
\-\ punctate\\:\\ 0\\.04108327897250403\ \(0\)\
\-\ affect\\:\\ 0\\.04080115078108117\ \(0\)\
\-\ and\\:\\ 0\\.040732321916024675\ \(0\)\
\-\ periphery\\:\\ 0\\.03977539326709655\ \(0\)\
\-\ continue\\:\\ 0\\.03867606837759766\ \(0\)\
\-\ approach\\:\\ 0\\.037817024364281845\ \(0\)\
\-\ 2002\\:\\ 0\\.037727846598414834\ \(0\)\
\-\ ddx\\:\\ 0\\.03746701636210134\ \(0\)\
\-\ scar\\:\\ 0\\.03721567299201813\ \(0\)\
\-\ 2001\\:\\ 0\\.03721567299201813\ \(0\)\
\-\ significantly\\:\\ 0\\.03705304946625374\ \(0\)\
\-\ germ\\:\\ 0\\.036816071474370174\ \(0\)\
\-\ neoplasms\\:\\ 0\\.0367388507719763\ \(0\)\
\-\ analysis\\:\\ 0\\.036662483354473134\ \(0\)\
\-\ undergoing\\:\\ 0\\.035806398950493916\ \(0\)\
\-\ larger\\:\\ 0\\.035289434230585705\ \(0\)\
\-\ granulomatous\\:\\ 0\\.035044765106278145\ \(0\)\
\-\ followup\\:\\ 0\\.034808462397111765\ \(0\)\
\-\ that\\:\\ 0\\.0342169803599462\ \(0\)\
\-\ much\\:\\ 0\\.03414447877150024\ \(0\)\
\-\ symmetric\\:\\ 0\\.033784707833717474\ \(0\)\
\-\ per\\:\\ 0\\.03271934458977577\ \(0\)\
\-\ 36\\:\\ 0\\.03263402028426149\ \(0\)\
\-\ frequently\\:\\ 0\\.032466468297214605\ \(0\)\
\-\ be\\:\\ 0\\.031985392888603824\ \(0\)\
\-\ 21\\:\\ 0\\.0315023477740442\ \(0\)\
\-\ references\\:\\ 0\\.031430728677554726\ \(0\)\
\-\ us\\:\\ 0\\.031359844148846516\ \(0\)\
\-\ where\\:\\ 0\\.030982465097173274\ \(0\)\
\-\ infarction\\:\\ 0\\.030949158136499202\ \(0\)\
\-\ pathology\\:\\ 0\\.030949158136499202\ \(0\)\
\-\ additional\\:\\ 0\\.030561513682324383\ \(0\)\
\-\ referred\\:\\ 0\\.02917178692189129\ \(0\)\
\-\ greater\\:\\ 0\\.029044505590315236\ \(0\)\
\-\ 40\\:\\ 0\\.028994242234487558\ \(0\)\
\-\ abnormalities\\:\\ 0\\.028557601412302312\ \(0\)\
\-\ diagnosed\\:\\ 0\\.028557601412302312\ \(0\)\
\-\ mm\\:\\ 0\\.028213690614719792\ \(0\)\
\-\ defined\\:\\ 0\\.028124799601999453\ \(0\)\
\-\ identified\\:\\ 0\\.027950375682724828\ \(0\)\
\-\ involving\\:\\ 0\\.02761420335061669\ \(0\)\
\-\ benign\\:\\ 0\\.027081552156013305\ \(0\)\
\-\ although\\:\\ 0\\.026839029694547524\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.026839029694547524\ \(0\)\
\-\ masses\\:\\ 0\\.026839029694547524\ \(0\)\
\-\ recent\\:\\ 0\\.02669390770183848\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.026395284181445378\ \(0\)\
\-\ study\\:\\ 0\\.02629289444259363\ \(0\)\
\-\ cancer\\:\\ 0\\.026259098869316332\ \(0\)\
\-\ several\\:\\ 0\\.025865939930282068\ \(0\)\
\-\ often\\:\\ 0\\.025724086310348303\ \(0\)\
\-\ no\\:\\ 0\\.025640401433973704\ \(0\)\
\-\ any\\:\\ 0\\.025478874568735137\ \(0\)\
\-\ approximately\\:\\ 0\\.02515531339458088\ \(0\)\
\-\ during\\:\\ 0\\.02497100431301518\ \(0\)\
\-\ demonstrated\\:\\ 0\\.024228862619110933\ \(0\)\
\-\ years\\:\\ 0\\.024166317568142345\ \(0\)\
\-\ evaluation\\:\\ 0\\.024042900342712913\ \(0\)\
\-\ all\\:\\ 0\\.023468102971647246\ \(0\)\
\-\ chronic\\:\\ 0\\.02340089484755452\ \(0\)\
\-\ months\\:\\ 0\\.022947894041750853\ \(0\)\
\-\ one\\:\\ 0\\.02257202817751683\ \(0\)\
\-\ is\\:\\ 0\\.021593000721476595\ \(0\)\
\-\ physical\\:\\ 0\\.02137653864194384\ \(0\)\
\-\ increased\\:\\ 0\\.021318565543780532\ \(0\)\
\-\ bilateral\\:\\ 0\\.02118785373335874\ \(0\)\
\-\ noted\\:\\ 0\\.02090248921269689\ \(0\)\
\-\ associated\\:\\ 0\\.020779346873154206\ \(0\)\
\-\ can\\:\\ 0\\.020688408969505225\ \(0\)\
\-\ small\\:\\ 0\\.020336170654771737\ \(0\)\
\-\ exam\\:\\ 0\\.01984600638239407\ \(0\)\
\-\ demonstrates\\:\\ 0\\.01980613407393457\ \(0\)\
\-\ large\\:\\ 0\\.019753326321586974\ \(0\)\
\-\ have\\:\\ 0\\.01969439595158423\ \(0\)\
\-\ multiple\\:\\ 0\\.019283083046319486\ \(0\)\
\-\ seen\\:\\ 0\\.018560448613723413\ \(0\)\
\-\ male\\:\\ 0\\.01755303278447381\ \(0\)\
\-\ as\\:\\ 0\\.0158379761310212\ \(0\)\
\-\ there\\:\\ 0\\.01568664382599184\ \(0\)\
\-\ not\\:\\ 0\\.015563614319161891\ \(0\)\
\-\ an\\:\\ 0\\.015075563532940026\ \(0\)\
\-\ are\\:\\ 0\\.014959573596985432\ \(0\)\
\-\ pain\\:\\ 0\\.014107319003981322\ \(0\)\
\-\ was\\:\\ 0\\.013739616282755043\ \(0\)\
\-\ this\\:\\ 0\\.013546758868806344\ \(0\)\
\-\ patient\\:\\ 0\\.01282261257566202\ \(0\)\
\-\ year\\:\\ 0\\.012149666975815104\ \(0\)\
\-\ on\\:\\ 0\\.011906691742762314\ \(0\)\
\-\ old\\:\\ 0\\.011667886008377537\ \(0\)\
